# US 2025/0154487 A1 · Engineered alpha klotho polypeptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154487 A1
- Document ID: US20250154487A1
- Status: Published application
- Kind: A1
- Application number: 18/941,264
- Filed: 2024-11-08
- Published: 2025-05-15
- Earliest claimed: 2023-11-10
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Marc EGERMAN; Chauhongduc PHAN; Nianshuang WANG; Yang SHEN; Xin WANG; Kishor DEVALARAJA-NARASHIMHA; David GLASS
- Web page: https://patentgrep.com/patent/US20250154487A1

## CPC

- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- A61P 13/12: of the kidneys
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2319/02: containing a signal sequence
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C12Y 302/01031: Beta-glucuronidase (3.2.1.31)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present disclosure provides engineered alpha klotho polypeptides and methods of their production and use. Soluble alpha klotho polypeptides disclosed herein comprise an alpha klotho moiety having one or more mutations for enhancing activity, production yield, and/or stability relative to human alpha klotho. The disclosure further provides pharmaceutical compositions comprising the engineered alpha klotho polypeptides, and methods of use of the engineered alpha klotho polypeptides in treatment methods, including treatment of age-related conditions and kidney disease. Also disclosed are nucleic acids encoding the engineered alpha klotho polypeptides, recombinant cells that express the engineered alpha klotho polypeptides, and methods of producing the engineered alpha klotho polypeptides.

## Claims

### Claim 1

A polypeptide which:
(a) comprises an alpha klotho KL2 domain having (i) at least about 80% sequence identity to SEQ ID NO:3 and (ii) an amino acid substitution at the position corresponding to amino acid C521 of SEQ ID NO:1; and
(b) lacks a cysteine at the amino acid corresponding to amino acid C970 of SEQ ID NO:1, if present.

### Claim 2 (depends on 1)

The polypeptide of claim 1, which lacks an amino acid corresponding to amino acid C970 of SEQ ID NO:1.

### Claim at position 3

-4. (canceled)

### Claim 5 (depends on 1)

The polypeptide of claim 1, wherein the amino acid substitution at the position corresponding to amino acid C521 of SEQ ID NO:1 is a cysteine to serine mutation.

### Claim 6 (depends on 1)

The polypeptide of claim 1, which comprises a C-terminal deletion of at least 21 amino acids as compared to the amino acid sequence of SEQ ID NO:13

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The polypeptide of claim 1, wherein the alpha klotho KL2 domain has at least about 95% sequence identity to SEQ ID NO:3.

### Claim 9 (depends on 1)

The polypeptide of claim 1, wherein the alpha klotho KL2 domain has at least about 99% sequence identity to SEQ ID NO:4.

### Claim 10 (depends on 1)

The polypeptide of claim 1, further comprising an alpha klotho KL1 domain having at least about 80% sequence identity to SEQ ID NO:9 or to SEQ ID NO:10.

### Claim 11

(canceled)

### Claim 12 (depends on 10)

The polypeptide of claim 10, wherein the alpha klotho KL1 domain comprises an amino acid substitution at the position corresponding to position C370 of SEQ ID NO:1, which is optionally a cysteine to serine substitution.

### Claim 13 (depends on 1)

The polypeptide of claim 1, which comprises an amino acid sequence having at least about 99% sequence identity to SEQ ID NO:12.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The polypeptide of claim 1, which comprises an amino acid sequence having at least about 95%, sequence identity to SEQ ID NO:16.

### Claim at position 15

-17. (canceled)

### Claim 18 (depends on 1)

The polypeptide of claim 1, further comprising a signal peptide.

### Claim 19 (depends on 1)

The polypeptide of claim 1, further comprising a stabilization moiety to the alpha klotho KL2 domain.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The polypeptide of claim 19, wherein the stabilization moiety comprises an Fc domain comprising a CH2 domain and a CH3 domain.

### Claim 22 (depends on 21)

The polypeptide of claim 21, wherein the Fc domain further comprises an additional CH3 domain connected to the CH3 domain via a linker.

### Claim 23 (depends on 21)

The polypeptide of claim 21, wherein the Fc domain is a non-dimerizing Fc domain.

### Claim 24 (depends on 19)

The polypeptide of claim 19, wherein the stabilization moiety is an albumin moiety.

### Claim 25 (depends on 24)

The polypeptide of claim 24, wherein the albumin moiety is human serum albumin.

### Claim 26

(canceled)

### Claim 27 (depends on 24)

The polypeptide of claim 24, wherein the albumin moiety comprises the amino acid sequence of SEQ ID NO:20.

### Claim 28 (depends on 19)

The polypeptide of claim 19, further comprising a linker.

### Claim 29 (depends on 28)

The polypeptide of claim 28, wherein the polypeptide comprises, in N- to C-terminal order: an alpha klotho moiety comprising the KL2 domain, the linker, and the stabilization moiety.

### Claim 30 (depends on 28)

The polypeptide of claim 28, wherein the polypeptide comprises, in N- to C-terminal order: the stabilization moiety, the linker, and an alpha klotho moiety comprising the alpha klotho KL2 domain.

### Claim at position 29

-32. (canceled)

### Claim 33

A polypeptide comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO:16, wherein the position corresponding to amino acid 488 of SEQ ID NO:16 is not a cysteine and which lacks an amino acid sequence having at least 80% sequence identity to SEQ ID NO:8.

### Claim 34 (depends on 33)

The polypeptide of claim 33, wherein the position corresponding to amino acid 488 of SEQ ID NO:16 is a serine.

### Claim 35 (depends on 33)

The polypeptide of claim 33, which comprises the amino acid sequence of SEQ ID NO: 16.

### Claim 36

(canceled)

### Claim 37 (depends on 33)

The polypeptide of claim 33, which comprises the amino acid sequence of SEQ ID NO:62.

### Claim 38 (depends on 1)

A nucleic acid encoding the polypeptide of claim 1.

### Claim 39 (depends on 1)

A host cell engineered to express the polypeptide of claim 1.

### Claim 40 (depends on 39)

A method of producing a polypeptide, comprising culturing the host cell of claim 39 and recovering the polypeptide expressed thereby.

### Claim at position 38

-42. (canceled)

### Claim 43 (depends on 1)

A pharmaceutical composition comprising the polypeptide of claim 1 and an excipient.

### Claim 44 (depends on 1)

A method of activating FGFR signaling in a cell, the method comprising contacting the cell with the polypeptide of claim 1.

### Claim 45 (depends on 44)

The method of claim 44, wherein the cell is a kidney cell.

### Claim at position 42

-47. (canceled)

### Claim 48 (depends on 1)

A method of preventing an age-related condition in a subject or of treating a subject suffering from an age-related condition, the method comprising administering to the subject the polypeptide of claim 1.

### Claim 49

(canceled)

### Claim 50 (depends on 1)

A method of preventing kidney disease in a subject or of treating a subject suffering from kidney disease, the method comprising administering to the subject the polypeptide of claim 1.
